Search

Your search keyword '"Chen, Qiang"' showing total 39 results
Start Over Author "Chen, Qiang" Journal medicine
39 results on '"Chen, Qiang"'

28. Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy

Author

Chen Qiang, Jiang Feng, Qiu Mantang, Xu Lin, Mao Qixing, Yin Rong, Xia Wenjie, and Dong Gaochao

Subjects
Oncology, medicine.medical_specialty, Lung Neoplasms, Esophageal Neoplasms, medicine.medical_treatment, Polymorphism, Single Nucleotide, Internal medicine, medicine, Humans, Survival analysis, Neoadjuvant therapy, Xeroderma Pigmentosum Group D Protein, business.industry, Hazard ratio, General Medicine, Odds ratio, Esophageal cancer, Endonucleases, medicine.disease, Survival Analysis, Neoadjuvant Therapy, Surgery, DNA-Binding Proteins, Clinical trial, Meta-analysis, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, ERCC1, business, Systematic Review and Meta-Analysis, Research Article
Abstract

Supplemental Digital Content is available in the text, Excision repair cross complementing 1 (ERCC1) and xeroderma pigmentosum group D (XPD) play important roles in the nucleotide excision repair (NER) pathway. The correlation between ERCC1 polymorphisms (rs11615 and rs3212986) and XPD polymorphisms (rs13181 and rs1799793) with the response rate and overall survival of cancer patients who accept neoadjuvant therapy has been extensively investigated. However, the results are inconclusive. In this study, we performed a meta-analysis to determine the strength of this correlation. A comprehensive literature search was conducted in Medline, PubMed, and Embase up to February 2015. A review of all titles and abstracts was performed by 2 of the authors to screen the articles based on the eligibility criteria. Clinical trials, observational studies, and epidemiological studies describing ERCC polymorphisms and neoadjuvant treatment were considered for review. The response rate was analyzed using pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Overall survival was assessed using the hazard ratio (HR) with corresponding 95% confidence intervals. In the present meta-analysis, we demonstrated that the ERCC1 rs3212986 polymorphism was significantly correlated with the response rate of esophageal cancer patients to neoadjuvant therapy (OR = 0.49, 95% CI = 0.31–0.76, heterogeneity P = 0.480). Furthermore, a considerable correlation was observed between ERCC1 rs11615 and the response rate of esophageal cancer patients to neoadjuvant therapy (OR = 0.228, 95% CI = 0.125–0.418, heterogeneity P = 0.291). No correlation was observed in the meta-analysis of overall survival. The individual studies included in our study differed in their patient selection and therapeutic protocols, which might lead to some bias in the results. These findings indicate that the ERCC1 rs11615 and ERCC1 rs312986 polymorphisms may be candidate pharmacogenomic factors capable of predicting the response rate of esophageal cancer patients who accept neoadjuvant therapy. Further studies are warranted.

Published
2015

39. Paradoxical cognitive and language function recovery by zolpidem in a patient with traumatic brain injury: A case report.

Author

Li J, Li H, Peng C, Xu W, Chen Q, and Liu G

Subjects
Humans, Male, Adult, Cognition drug effects, Recovery of Function drug effects, Language, Pyridines therapeutic use, Zolpidem therapeutic use, Zolpidem administration & dosage, Brain Injuries, Traumatic complications, Brain Injuries, Traumatic drug therapy, Spectroscopy, Near-Infrared
Abstract

Background: Traumatic brain injury (TBI) is a significant public health issue, often resulting from traffic accidents and falls, leading to a wide spectrum of outcomes from mild concussions to severe brain damage. The neurorehabilitation of TBI focuses on enhancing recovery and improving quality of life. Zolpidem, traditionally used for short-term management of insomnia, has shown potential in improving cognitive functions and language in TBI patients. Advances in neuroimaging techniques, such as functional near-infrared spectroscopy (fNIRS), have facilitated the exploration of the effects of therapeutic interventions on brain activity and functional connectivity in TBI patients., Case Summary: We present the case of a 34-year-old male who sustained a TBI from a traffic collision. Despite severe impairments in cognitive and language functions, administration of 10 mg of zolpidem resulted in temporary but significant improvements in these areas, as evidenced by increased Mini-Mental State Examination scores and observed behavioral changes. fNIRS assessments before and after zolpidem administration revealed notable changes in cerebral cortex activity, including increased left hemisphere activation and a shift in functional connectivity to the bilateral frontal lobes, corresponding with the patient's improvement., Conclusion: This case study highlights the potential of zolpidem, a medication traditionally used for insomnia, in enhancing cognitive and verbal functions in a patient with TBI, suggesting a potential therapeutic role for zolpidem in neurorehabilitation, supported by changes in brain activity and connectivity observed through fNIRS. However, further investigation is warranted to validate these findings and elucidate zolpidem's long-term effects on cognitive and functional outcomes in TBI patients., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results